cyclacel
announces
fadraciclib
abstract
selected
oral
presentation
late
breaking
best
proffered
paper
session
symposium
berkeley
heights
globe
newswire
cyclacel
pharmaceuticals
nasdaq
cycc
nasdaq
cyccp
cyclacel
company
biopharmaceutical
company
developing
innovative
medicines
based
cancer
cell
biology
announced
abstract
highlighting
clinical
data
cyclacel
inhibitor
fadraciclib
selected
oral
presentation
ena
symposium
held
virtually
october
data
ongoing
phase
study
fadraciclib
single
agent
patients
advanced
solid
tumors
details
presentations
follows
title
phase
safety
pharmacokinetic
pharmacodynamic
study
fadraciclib
cyclin
dependent
kinase
inhibitor
patients
advanced
cancers
session
title
late
breaking
best
proffered
papers
session
date
time
saturday
october
cet
presentation
number
program
accessed
website
kinases
fadraciclib
kinases
cdks
critical
cell
cycle
regulation
transcriptional
elongation
dysregulated
cdks
linked
cancer
hallmarks
uncontrolled
proliferation
increased
survival
fadraciclib
potent
orally
intravenously
available
inhibitor
part
phase
study
fadraciclib
single
agent
patients
advanced
solid
tumors
target
engagement
durable
suppression
biomarker
observed
single
dose
fadraciclib
tumor
shrinkage
stable
disease
observed
five
patients
cyclin
e
myc
amplified
cancers
ongoing
part
study
evaluating
intensive
dosing
regimen
part
heavily
pretreated
patient
amplified
endometrial
cancer
achieved
radiographically
confirmed
partial
response
pr
month
half
fadraciclib
fadraciclib
also
evaluated
phase
combination
studies
venetoclax
patients
relapsed
refractory
cll
aml
mds
preclinical
data
suggest
fadraciclib
may
benefit
patients
adult
pediatric
hematological
malignancies
aml
lymphomas
cll
multiple
myeloma
certain
cyclin
solid
tumors
including
certain
forms
breast
cancer
neuroblastoma
ovarian
cancer
uterine
serous
carcinoma
cyclacel
pharmaceuticals
cyclacel
pharmaceuticals
biopharmaceutical
company
developing
innovative
cancer
medicines
based
cell
cycle
transcriptional
regulation
dna
damage
response
biology
transcriptional
regulation
program
evaluating
fadraciclib
single
agent
solid
tumors
combination
venetoclax
patients
relapsed
refractory
aml
mds
cll
dna
damage
response
program
evaluating
oral
combination
sapacitabine
venetoclax
patients
relapsed
refractory
aml
mds
trial
ist
evaluating
oral
combination
sapacitabine
olaparib
patients
brca
mutant
breast
cancer
program
evaluating
inhibitor
advanced
leukemias
mds
patients
cyclacel
strategy
build
diversified
biopharmaceutical
business
focused
hematology
oncology
based
pipeline
novel
drug
candidates
additional
information
please
visit
statements
news
release
contains
certain
statements
involve
risks
uncertainties
could
cause
actual
results
materially
different
historical
results
future
results
expressed
implied
statements
statements
include
statements
regarding
among
things
efficacy
safety
intended
utilization
cyclacel
product
candidates
conduct
results
future
clinical
trials
plans
regarding
regulatory
filings
future
research
clinical
trials
plans
regarding
partnering
activities
factors
may
cause
actual
results
differ
materially
include
risk
product
candidates
appeared
promising
early
research
clinical
trials
demonstrate
safety
efficacy
later
clinical
trials
trials
may
difficulty
enrolling
cyclacel
may
obtain
approval
market
product
candidates
risks
associated
reliance
outside
financing
meet
capital
requirements
risks
associated
reliance
collaborative
partners
clinical
trials
development
commercialization
product
candidates
urged
consider
statements
include
words
may
would
could
believes
estimates
projects
potential
expects
plans
anticipates
intends
continues
forecast
designed
goal
negative
words
comparable
words
uncertain
list
description
risks
uncertainties
company
faces
please
refer
recent
annual
report
form
periodic
filings
file
securities
exchange
commission
available
statements
current
date
made
assume
obligation
update
statements
whether
result
new
information
future
events
otherwise
contacts
company
paul
mcbarron
pmcbarron
investor
relations
russo
partners
llc
eric
ando
copyright
cyclacel
pharmaceuticals
rights
reserved
cyclacel
logo
trademarks
cyclacel
pharmaceuticals
inc
